| abstract |
The present disclosure relates to a new, stable, oil based liquid suspension filled hard capsule dosage form for bismuth salts such as bismuth subsalicylate, a process for its manufacture, methods to deliver bismuth salts to humans or animals via stable hard capsules, and improved methods of treating gastrointestinal disorders with such dosage forms. |